Proteostasis Therapeutics (Proteostasis Therapeutics) LT-Debt-to-Total-Asset : 0.20 (As of Sep. 2020)

View and export this data going back to 2016. Start your Free Trial

What is Proteostasis Therapeutics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Proteostasis Therapeutics's long-term debt to total assests ratio for the quarter that ended in Sep. 2020 was 0.20.

Proteostasis Therapeutics's long-term debt to total assets ratio increased from Sep. 2019 (0.13) to Sep. 2020 (0.20). It may suggest that Proteostasis Therapeutics is progressively becoming more dependent on debt to grow their business.

Proteostasis Therapeutics LT-Debt-to-Total-Asset Historical Data

The historical data trend for Proteostasis Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Proteostasis Therapeutics LT-Debt-to-Total-Asset Chart

Proteostasis Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.10

0.14

Proteostasis Therapeutics Quarterly Data
	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.13	0.14	0.16	0.18	0.20

Proteostasis Therapeutics LT-Debt-to-Total-Asset Calculation

Proteostasis Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2019 is calculated as

LT Debt to Total Assets (A: Dec. 2019 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2019 )	/	Total Assets (A: Dec. 2019 )
	=	12.043	/	84.724
	=	0.14

Proteostasis Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2020 is calculated as

LT Debt to Total Assets (Q: Sep. 2020 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2020 )	/	Total Assets (Q: Sep. 2020 )
	=	11.109	/	54.351
	=

Proteostasis Therapeutics (NAS:PTI) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Proteostasis Therapeutics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Proteostasis Therapeutics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Proteostasis Therapeutics (Proteostasis Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Proteostasis Therapeutics Inc (NAS:PTI) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

80 Guest Street, Suite 500, 5th Floor, Boston, MA, USA, 02135

Website

http://www.proteostasis.com

Proteostasis Therapeutics Inc is a United States-based clinical-stage biopharmaceutical company committed to the discovery and development of novel therapeutics to treat cystic fibrosis (CF) through theratyping, or the process of matching modulators to individual response to treatment regardless of cystic fibrosis transmembrane conductance regulator (CFTR) mutations. All of the company's revenue is collaboration or license revenue earned from activities in the United States.

Executives

Franklin M Berger	director	1000 MARINA BLVD, STE 200, BRISBANE CA 94005
Badrul A. Chowdhury	director	PROTEOSTASIS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 500, BOSTON MA 02135
Kimberlee C Drapkin	director	PREDIX PHARMACEUTICALS HOLDINGS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Jeffrey W. Kelly	director	200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Emmanuel Dulac	director	PROTEOSTASIS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 500, BOSTON MA 02135
David Arkowitz	director	C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Michael Alfieri	officer: Interim Head of Finance	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Greffrey S. Gilmartin	officer: Chief Medical Officer	200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Meenu Chhabra	director, officer: President and CEO	C/O VALLON PHARAMCEUTICALS, INC., 100 N 18TH, STREET, SUITE 300, PHILADELPHIA PA 19103
Sheila Wilson	officer: Chief Operating Officer	C/O PROTEOSTASIS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 500, BOSTON MA 02135
Benito Munoz	officer: Chief Scientific Officer	200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Eric D Larson	officer: See Remarks	C/O NORTHERN POWER SYSTEMS CORP., 29 PITMAN ROAD, BARRE VT 05641
Marija Zecevic	officer: Chief Commercial Officer	200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
New Enterprise Associates 12, Limited Partnership	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202
Peter J Barris	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202